Health Care · Pharmaceutical Preparations

RNA Atrium Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 209310136 filings
Russell 2000

RNA at a glance

Atrium Therapeutics, Inc. (RNA, SEC CIK 2093101) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as September 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Atrium Therapeutics, Inc. (RNA) shares worth $40.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
22 funds
$40.7M · −1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Collaboration revenue $15.3M, up $3.0M YoY, driven by a $15.0M BMS milestone
  • Net loss $4.3M vs $0.0M YoY, with operating expenses $22.0M vs $12.6M
  • Best program: ATR 1086 R&D spending $3.1M, up from $2.1M YoY
  • Operating cash outflow $60.4M, cash and equivalents $44.6M, short-term investments $187.5M
  • October PIPE generated $46.5M net proceeds, with proof-of-concept data anticipated in second half of 2027

Risk Factors

  • Newly added financing risk: October 2026 Offering sold 5,170,384 shares and warrants, diluting existing stockholders
  • Most material regulatory update: FDA cleared ATR 1072 IND in July 2026, but leadership changes may increase development uncertainty
  • Compliance exposure: Federal Anti-Kickback Statute and False Claims Act violations could trigger civil or criminal penalties
  • Near-term execution risk: First Corventis Phase 1/2 patient dosed in October 2026, with rare cardiac populations complicating enrollment
  • Liquidity risk: $44.6 million cash and $187.5 million short-term investments fund operations for at least 12 months

AI summary of the RNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • First patient dosed in Phase 1/2 Corventis trial for PRKAG2 syndrome, with initial proof-of-concept data expected in the second half of 2027
  • Nonclinical ATR 1072 data showed reversal of cardiac glycogen accumulation and improvements in hypertrophy and ECG conduction measures
Filed Nov 2, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Upcoming November 6, 2026 poster presentation at HCMS during American Heart Association Scientific Sessions 2026
  • Investor relevance: conference data may influence clinical-development expectations and Atrium’s valuation

Item 8.01: Other Events

  • New mouse-model data to be presented November 6, 2026, at AHA Scientific Sessions in Chicago
  • Single-dose mATR 1072 reversed cardiac glycogen accumulation after established disease in mice

Item EX-99.1: Item EX-99.1

  • Atrium will present preclinical ATR 1072 data at AHA Scientific Sessions on November 6, 2026
  • Mouse surrogate mATR 1072 reversed cardiac glycogen accumulation and improved hypertrophy and ECG abnormalities

Item EX-99.2: Item EX-99.2

  • Investor presentation outlines Atrium’s post-launch progress since February 2026, including ATR 1072 trial clearance and first patient dosing
  • ATR 1072 Phase 1/2 Corventis trial targets PRKAG2 syndrome, with approximately 37 participants and initial proof-of-concept data expected in 2H 2027
Filed Oct 27, 2026Full analysis →

Item 8.01: Other Events

  • First patient dosed in Phase 1/2 Corventis trial of ATR 1072 for PRKAG2 syndrome
  • Clinical-stage milestone advances lead program into human testing

Item EX-99.1: Item EX-99.1

  • First patient dosed in Corventis, a Phase 1/2 trial testing ATR 1072 for PRKAG2 syndrome
  • Approximately 37 participants planned across dose-escalation and expansion cohorts

AI summaries of RNA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RNA

Don't miss the next RNA filing

  • Alerts as it files. A push when RNA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RNA, by share count.
  • Ask anything. An AI agent that reads every RNA filing and answers with sources.

RNA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Winslow Brendan R.FSep 18, 2026$8.95
Boyce SarahFSep 18, 2026$8.95
Hughes Steven GeorgeFSep 18, 2026$8.95
Younis HusamFSep 18, 2026$8.95
Hoyos Rocio MartinFSep 18, 2026$8.95
Kenney StephanieFSep 18, 2026$8.95
Flanagan W. MichaelFSep 18, 2026$8.95
Gallagher Kathleen P.FSep 18, 2026$8.95

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RNA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RNA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$40.7M
Q2 202623$75.4M
Q1 202621$71.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 66 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RNA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
8-KNov 2, 2026Analysis-
8-KOct 27, 2026Analysis-
8-KOct 9, 2026Analysis-
8-KOct 8, 2026Analysis-
4Sep 22, 2026--
4Sep 22, 2026--
4Sep 22, 2026--
4Sep 22, 2026--
4Sep 22, 2026--
4Sep 22, 2026--
4Sep 22, 2026--
4Sep 22, 2026--
SC 13GAug 14, 2026-
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
8-KJul 14, 2026Analysis-
SC 13GMay 15, 2026-
8-KMay 14, 2026Analysis
10-QMay 14, 2026Analysis
SC 13GApr 27, 2026-
4Apr 22, 2026--
4Apr 22, 2026--
4Apr 22, 2026--

Related Health Care companies

All Health Care →

RNA SEC filings: frequently asked questions

Which institutions hold RNA stock?

As of September 30, 2026, the largest Atrium Therapeutics, Inc. (RNA) holders among the 13F filers tracked by SignalX were BlackRock ($10.1 million), Vanguard Capital Management LLC ($6.0 million), T. Rowe Price Group ($5.3 million), Bank of America Corp ($3.9 million), Two Sigma Investments ($3.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did RNA report in its latest 8-K?

Atrium Therapeutics, Inc. (RNA) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest RNA SEC filings?

Atrium Therapeutics, Inc. (RNA) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on September 22, 2026.

What is RNA's SEC CIK number?

Atrium Therapeutics, Inc. (RNA)'s SEC Central Index Key (CIK) is 2093101. EDGAR lists every RNA filing under that number.

Ask anything about RNA

The research agent reads RNA's filings, financials, insider trades and 13F holders, then answers with sources.